Drawing for AIMPHARMA

USPTO serial 85674444

AIMPHARMA

Reviewed by CopyMark Law Group

Reg. 4433507Status 710
Filing date
Status date
Registration date
Nov 12, 2013
Examiner
MCCAULEY, BRENDAN D
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.

Status 710: Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active.

Need help with AIMPHARMA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Paul A. McLean

PAUL A. MCLEAN DLA PIPER LLP US2000 UNIVERSITY AVEEAST PALO ALTO, CA 94303-2214UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Adjuvants for medical purposes; adrenal hormone preparations; anesthetics for surgical and non-surgical use; analgesic preparations; analgesics; androgen preparations; anti-allergic medicines; antibacterial substances for medical purposes; antibiotic preparations; antibiotics; anticoagulants; antidepressants; anti-diabetic preparations; antidotes; antiemetics; antifungal creams for medical use; antifungal preparations; antihypertensives; antimicrobials for dermatologic use; antiseptic preparations; antitoxic sera; anti-cancer preparations; anti-cough drops; anti-dermoinfectives; anti-infective products for veterinary use; anti-inflammatory and antipyretic preparations; anti-sarcoma preparations; anti-uric preparations; appetite suppressants; bacterial and bacteriological preparations for medical or veterinary purposes; biological preparations for the treatment of cancer; chemical reagents for medical or veterinary purposes; chemotherapeutics; composite materials for dental and dental technical purposes; diagnostic preparations for medical purposes; diagnostic reagents for medicinal use; ferments for medical or veterinary use; fungicides for medical use; gases and gas mixtures for medical imaging use; gastrointestinal cleaning agents; gels, creams and solutions for dermatological use; general anesthetics; glucose for medical purposes; hormones for medical purposes; inhalant anesthetics; inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; insulin; Intravenous fluids used for rehydration, nutrition and the delivery of pharmaceutical preparations; lipotropic factor preparations; local anesthetics; medicinal herbal extracts for medical purposes; medicines for the treatment of gastrointestinal diseases; milk ferments for pharmaceutical purposes; nutritive substances for micro-organisms for medical use; ophthalmic preparations; ophthalmologic preparations; oral vaccine preparations; pancreas hormone preparations; penicillin preparations; pharmaceutical anti-allergic preparations and substances; pharmaceutical for the treatment of erectile dysfunction; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; pharmaceutical preparations for animal skincare; pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; pharmaceutical preparations for ocular or intraocular surgery; pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; pharmaceutical preparations for treating allergic rhinitis and asthma; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for treating skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for wounds; pharmaceutical preparations for skin care; pharmaceutical preparations for treating allergies; pharmaceutical preparations for treating hypertension; pharmaceutical products and preparations for preventing skin blemishes during pregnancy; pharmaceutical products for the treatment of bone diseases; pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; pharmaceutical products for treating respiratory diseases and asthma; pharmaceutical products for the prevention and treatment of cancer; pharmaceutical solutions used in dialysis; pharmaceuticals for the treatment of erectile dysfunction; pheromones for medical use; pituitary hormone preparations; preparations for detecting genetic predispositions for medical purposes; preparations for detecting mutation in prion genes for medical purposes; preparations for the treatment of asthma; radio-isotope markers for therapeutic or diagnostic use; reagents and media for medical and veterinary diagnostic purposes; reagents for medical use; stem cells for medical purposes; surgical tissues; tetracycline preparations; thyroid and para-thyroid hormone preparations; topical analgesic creams; trichomycin preparations; tumor suppressing agents; vaccine preparations; vaccines for cattle; vasoconstrictors; veterinary preparations for treatment of intestinal bacteria; virucides; yeast or yeast extracts for medical, veterinary or pharmaceutical purposesSECTION 8 - CANCELLEDJul 8, 2013

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jun 19, 2020C8..CANCELLED SEC. 8 (6-YR)—
Nov 12, 2018REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Nov 12, 2013R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Oct 9, 2013SUNANOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED—
Oct 8, 2013REGVLAW OFFICE REGISTRATION REVIEW COMPLETED—
Sep 30, 2013CNPRALLOWED PRINCIPAL REGISTER - SOU ACCEPTED—
Sep 27, 2013SUPCSTATEMENT OF USE PROCESSING COMPLETE—
Sep 13, 2013AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Aug 16, 2013IUAFUSE AMENDMENT FILED—
Aug 16, 2013EISUTEAS STATEMENT OF USE RECEIVEDThe applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action.
Feb 26, 2013NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Jan 1, 2013NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jan 1, 2013PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Dec 12, 2012NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Nov 26, 2012PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Nov 26, 2012ALIEASSIGNED TO LIE—
Nov 6, 2012CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Nov 6, 2012XAECEXAMINER'S AMENDMENT ENTERED—
Nov 6, 2012GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Nov 6, 2012GNEAEXAMINERS AMENDMENT E-MAILED—
Nov 6, 2012CNEAEXAMINERS AMENDMENT -WRITTEN—
Nov 1, 2012DOCKASSIGNED TO EXAMINER—
Jul 19, 2012MDSMNOTICE OF DESIGN SEARCH CODE MAILED—
Jul 18, 2012NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jul 14, 2012NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance